Form 4 for GLUE Monte Rosa Therapeutics, Inc.
Accepted 2026-07-16 16:10:42 ET · period of report 2026-07-15 · accession 0001193125-26-306110 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-16 16:10 | 2026-07-15 | GLUE | Champoux Jennifer | COO | M - OptEx | $3.98 | +4,351 | 66.7K | +7% | +$17.3K |
| DT | 2026-07-16 16:10 | 2026-07-15 | GLUE | Champoux Jennifer | COO | S - Sale+OE | $23.38 | -4,351 | 62.4K | -7% | -$101.7K |
| DT | 2026-07-16 16:10 | 2026-07-15 | GLUE | Champoux Jennifer | COO | M - OptEx | $0.00 | -4,351 | 26.9K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-15 | M | A | 4,351 | $3.98 | 66,722 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026. |
| 2 | Common | Common Stock | 2026-07-15 | S | D | 4,351 | $23.38 | 62,371 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-07-15 | M | D | 4,351 | $0.00 | 26,947 | D | $3.98 · — to 2034-06-03 | 4,351 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026. (F3) 25% of the shares underlying this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |